Careers in Israel
Careers in the US
Board of Directors
Scientific Advisory Board
Johns Hopkins University
Annual and Quarterly Reports
pioneer in computational drug target discovery
Innovative immuno-oncology pipeline
Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients with Advanced Malignancies
Mar 17, 2020
Compugen Announces Closing of $75 Million Public Offering of Ordinary Shares
Research and Development
Our optimized process for predictive discovery of novel drug targets
Our ongoing Phase 1 study of COM701, a first-in-class antibody targeting PVRIG, a novel ICP target
Compugen, FROM CODE TO CURE®(video)
COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint target candidate discovered computationally by Compugen.
BAY 1905254/ILDR2 (partnered)
ILDR2 (formerly CGEN-15001T) is a novel immune checkpoint target discovered by Compugen and partnered to Bayer.
COM902, an anti-TIGIT inhibitor, is being developed as an integral component of the COM701 program, to facilitate the combination strategy for COM701.
COM902 is being developed as an integral component of the COM701 program, to provide the company with an internally-developed antibody to facilitate the combination strategy for COM701
Multiple myeloid programs
Compugen’s early stage programs are focused largely on myeloid targets addressing a range of mechanisms of action.
Feb 20, 2020
Compugen Fourth Quarter and Full Year 2019 Conference Call
Jan 23, 2020
Compugen to be added to TASE-90 and TASE-125 Indexes
(effective date - February 6, 2020)
Feb 06, 2020
COM701 Phase 1 Study Trial-in-Progress Poster Presentation, The ASCO-SITC Clinical Immuno-Oncology Symposium
Click here for more info about partnering with Compugen